{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T18:45:56Z","timestamp":1782499556924,"version":"3.54.5"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T00:00:00Z","timestamp":1687824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.yebeh.2023.109335","type":"journal-article","created":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T19:26:19Z","timestamp":1688844379000},"page":"109335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Patterns of psychotropic drug use in veterans with epilepsy: Do drug interactions matter?"],"prefix":"10.1016","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6681-7134","authenticated-orcid":false,"given":"Barry E.","family":"Gidal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3988-458X","authenticated-orcid":false,"given":"Rizwana","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tung","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariela","family":"Karasov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2023.109335_b0005","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1212\/WNL.0b013e31827b1ae0","article-title":"Depression in epilepsy: a systematic review and meta-analysis","volume":"80","author":"Fiest","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2023.109335_b0010","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1212\/CPJ.0000000000000874","article-title":"Psychiatric co-morbidities in people with epilepsy","volume":"11","author":"Mula","year":"2021","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.yebeh.2023.109335_b0015","article-title":"Mood and anxiety disorders and suicidality in patients with newly diagnosed focal epilepsy: an analysis of a complex comorbidity","author":"Kanner","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2023.109335_b0020","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/epi.17140","article-title":"ILAE clinical practice recommendations for the medical treatment of depression in adults with epilepsy","volume":"63","author":"Mula","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2023.109335_b0025","first-page":"2014","article-title":"Antidepressants for people with epilepsy and depression (review)","volume":"12","author":"Maguire","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.yebeh.2023.109335_b0030","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijlp.2017.10.003","article-title":"Antipsychotic augmentation for depressiove disorder: a review of clinical practice guidelines","volume":"55","author":"Simons","year":"2017","journal-title":"Int J Law Psychiatry"},{"key":"10.1016\/j.yebeh.2023.109335_b0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1528-1167.2012.03671.x","article-title":"Enzyme induction with antiepileptic drugs: cause for concern?","volume":"54","author":"Brodie","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2023.109335_b0040","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.phrs.2016.02.014","article-title":"Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics","volume":"106","author":"Spina","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.yebeh.2023.109335_b0045","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1517\/17425255.2014.956081","article-title":"Pharmacokinetic and pharmacodynamics interactions between antiepileptics and antidepressants","volume":"10","author":"Italiano","year":"2014","journal-title":"Exp Opin Drug Metabol Toxicol"},{"key":"10.1016\/j.yebeh.2023.109335_b0050","doi-asserted-by":"crossref","first-page":"149","DOI":"10.5698\/1535-7511-11.5.149","article-title":"Hippocampal atrophy: another common pathogenic mechanism of depressive disorders and epilepsy?","volume":"11","author":"Kanner","year":"2011","journal-title":"Epilepsy Curr"},{"issue":"7","key":"10.1016\/j.yebeh.2023.109335_b0055","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1176\/appi.ps.201500120","article-title":"Predictors of antidepressant nonadherence among older veterans with depression","volume":"67","author":"Kales","year":"2016","journal-title":"Psychiatr Serv"},{"issue":"5","key":"10.1016\/j.yebeh.2023.109335_b0060","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1176\/appi.ps.201400021","article-title":"Antidepressant self-discontinuation: results from the collaborative psychiatric epidemiology surveys","volume":"66","author":"Samples","year":"2015","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.yebeh.2023.109335_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2018.05.028","article-title":"Relationship between antipsychotic blood levels and treatment failure during the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study","author":"Melkote","year":"2018","journal-title":"Schizophr Res"},{"key":"10.1016\/j.yebeh.2023.109335_b0070","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0924-977X(02)00018-4","article-title":"Carbamazepine augmentation in depressive patients non-responding to citalopram; a pharmacokinetic and clinical pilot study","volume":"12","author":"Steinacher","year":"2002","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.yebeh.2023.109335_b0075","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0447.1989.tb07184.x","article-title":"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine","volume":"350","author":"Greb","year":"1989","journal-title":"Acta Psychiatry Scand Suppl"},{"key":"10.1016\/j.yebeh.2023.109335_b0080","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00228-002-0498-6","article-title":"Concomitant use of mirtazapine and phenytoin: a drug-drug interactionstudy in healthy male subjects","volume":"58","author":"Spaans","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2023.109335_b0085","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00007691-199902000-00013","article-title":"Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication","volume":"21","author":"Olesen","year":"1999","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.yebeh.2023.109335_b0090","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1365-2125.2005.02507.x","article-title":"Effects of cytochrome p450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics","volume":"61","author":"Grimm","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2023.109335_b0095","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/JCP.0000000000000564","article-title":"Raising the Minimum Effective Dose of Serotonin Reuptake Inhibitor Antidepressants","volume":"36","author":"Safer","year":"2016","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.yebeh.2023.109335_b0100","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1192\/S0007125000297377","article-title":"The evidence for 20 mg a day of fluoxetine as the optimal dose in the treatment of depression","author":"Altamura","year":"1988","journal-title":"Br J Psychiatry Suppl"},{"key":"10.1016\/j.yebeh.2023.109335_b0105","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00004850-200105000-00002","article-title":"The antidepressant effect of sertraline is not enhanced by dose titration: results from an outpatient clinical trial","volume":"16","author":"Schweizer","year":"2001","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.yebeh.2023.109335_b0110","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12916-018-1096-5","article-title":"Optimising first- and second-line treatment strategies for untreated major depressive disorder \u2013 the SUND study: a pragmatic multi-centre, assessor-blinded randomised controlled trial","volume":"16","author":"Kato","year":"2018","journal-title":"BMC Med"},{"issue":"6","key":"10.1016\/j.yebeh.2023.109335_b0115","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00406-005-0579-5","article-title":"Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review","volume":"255","author":"Adli","year":"2005","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"3","key":"10.1016\/j.yebeh.2023.109335_b0120","article-title":"Low dosage tricyclic antidepressants for depression","author":"Furukawa","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.yebeh.2023.109335_b0125","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0006-3223(93)90288-O","article-title":"Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients","volume":"33","author":"Nordstrom","year":"1993","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.yebeh.2023.109335_b0130","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D(2) occupancy, clinical response and side effects, a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.yebeh.2023.109335_b0135","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.jcp.0000117422.05703.ae","article-title":"Dose response and dose equivalence of antipsychotics","volume":"24","author":"Davis","year":"2004","journal-title":"J Clin Psychopharmacol"},{"issue":"302","key":"10.1016\/j.yebeh.2023.109335_b0140","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jad.2021.12.134","article-title":"Augmentation strategies for treatment resistant major depression: a systematic review and network meta-analysis","volume":"1","author":"Nu\u00f1ez","year":"2022","journal-title":"J Affect Disord"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505023002548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505023002548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T17:47:33Z","timestamp":1782496053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505023002548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":28,"alternative-id":["S1525505023002548"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2023.109335","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns of psychotropic drug use in veterans with epilepsy: Do drug interactions matter?","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2023.109335","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109335"}}